Bio-Thera Solutions, Ltd. (SHA:688177)

China flag China · Delayed Price · Currency is CNY
17.06
+0.69 (4.22%)
At close: Jun 18, 2026
Market Cap7.06B -28.4%
Revenue (ttm)980.25M +24.4%
Net Income-390.44M
EPS-0.94
Shares Out 414.08M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,492,728
Open16.34
Previous Close16.37
Day's Range16.01 - 17.33
52-Week Range16.00 - 36.32
Beta0.34
AnalystsStrong Buy
Price Target36.20 (+112.19%)
Earnings DateAug 21, 2026

About Bio-Thera Solutions

Bio-Thera Solutions, Ltd., a biopharmaceutical company, researches and develops novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, eye diseases, and other severe unmet medical needs in China and internationally. It offers QLETLI for the treatment of ankylosing spondylitis, rheumatoid arthritis, psoriasis, Crohn’s disease, and uveitis; POBEVCY to treat patients with metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, cervical cancer, and epitheli... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 1,426
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688177
Full Company Profile

Financial Performance

In 2025, Bio-Thera Solutions's revenue was 935.22 million, an increase of 25.84% compared to the previous year's 743.17 million. Losses were -331.94 million, -34.95% less than in 2024.

Financial Statements